Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lyons

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
European Journal of Clinical Nutrition|July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight ProgrammeM McQuigg, J Brown, J Broom, et al.
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
British Journal of Haematology|May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myelomaElizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
European Journal of Clinical Nutrition|July 30, 2005
Empowering primary care to tackle the obesity epidemic: the Counterweight ProgrammeM McQuigg, J Brown, J Broom, et al.
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
British Journal of Haematology|May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myelomaElizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Pageof 21